The serum concentration of GFAP, reflecting astrocyte damage, was higher in patients with progressive MS during relapse than healthy controls [50], but it increased in response to CNS injury, including BBB breakdown after TBI and intracerebral hemorrhaging [51]. Here, GFAP is linked to myeloid sarcoma.